Indaptus Therapeutics Files 8-K: Material Agreement & Equity Sales
Ticker: INDP · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1857044
| Field | Detail |
|---|---|
| Company | Indaptus Therapeutics, INC. (INDP) |
| Form Type | 8-K |
| Filed Date | Jan 14, 2025 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.01, $2,246,500, $1.065, $0.94, $25,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, 8-k
TL;DR
Indaptus Therapeutics (INDP) filed an 8-K on Jan 12, 2025, reporting a material definitive agreement and unregistered equity sales.
AI Summary
On January 12, 2025, Indaptus Therapeutics, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also reported on unregistered sales of equity securities and other events. This filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing mentions a material definitive agreement and unregistered equity sales, which can introduce financial and operational risks if not managed properly.
Key Numbers
- 001-40652 — Commission File Number (Identifies the company's filing with the SEC.)
- 86-3158720 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Indaptus Therapeutics, Inc. (company) — Registrant
- January 12, 2025 (date) — Date of earliest event reported
- 001-40652 (other) — Commission File Number
- 86-3158720 (other) — IRS Employer Identification No.
- 3 Columbus Circle 15th Floor New York 10019 (location) — Principal executive offices address
FAQ
What is the nature of the material definitive agreement entered into by Indaptus Therapeutics?
The filing states that Indaptus Therapeutics, Inc. entered into a material definitive agreement on January 12, 2025, but the specific terms and counterparty are not detailed in this document.
What type of equity securities were sold in the unregistered sales?
The filing reports unregistered sales of equity securities but does not specify the type or amount of securities sold.
What are the "Other Events" reported in this 8-K filing?
The filing lists "Other Events" as an item information category, but the specific events are not elaborated upon in the provided text.
When was Indaptus Therapeutics, Inc. incorporated?
Indaptus Therapeutics, Inc. was incorporated in Delaware, as stated in the filing.
What is the address of Indaptus Therapeutics' principal executive offices?
The principal executive offices of Indaptus Therapeutics, Inc. are located at 3 Columbus Circle, 15th Floor, New York, NY 10019.
Filing Stats: 1,705 words · 7 min read · ~6 pages · Grade level 12.5 · Accepted 2025-01-14 16:15:25
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value INDP Nasdaq Capital Mark
- $2,246,500 — saction for aggregate gross proceeds of $2,246,500. The Purchase Agreements provide for th
- $1.065 — n a combined basis for consideration of $1.065 for one Share and a Warrant to purchase
- $0.94 — Warrants will have an exercise price of $0.94 per Share. The Shares, the Warrants a
- $25,000 — ering, and a non-accountable expense of $25,000. In addition, Paulson is entitled to ce
- $1.175 — at an exercise price per share equal to $1.175. The Placement Agent Warrants are exerc
Filing Documents
- form8-k.htm (8-K) — 56KB
- ex10-1.htm (EX-10.1) — 251KB
- ex10-2.htm (EX-10.2) — 101KB
- ex10-3.htm (EX-10.3) — 105KB
- ex10-4.htm (EX-10.4) — 105KB
- ex99-1.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- 0001493152-25-002145.txt ( ) — 931KB
- indp-20250112.xsd (EX-101.SCH) — 3KB
- indp-20250112_lab.xml (EX-101.LAB) — 33KB
- indp-20250112_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 14, 2025 INDAPTUS THERAPEUTICS, INC. By: /s/ Nir Sassi Name: Nir Sassi Title: Chief Financial Officer